Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Connection

Michael Graner to Interferon-gamma

This is a "connection" page, showing publications Michael Graner has written about Interferon-gamma.

 
Connection Strength
 
 
 
0.268
 
  1. Zhang M, Wang H, Liao M, Chen X, Graner M, Zhu X, Zhang J, Yang Q, Lu H, Zhou B, Chen X. Diagnosis of latent tuberculosis infection in bacille Calmette-Gu?rin vaccinated subjects in China by interferon-gamma ELISpot assay. Int J Tuberc Lung Dis. 2010 Dec; 14(12):1556-63.
    View in: PubMed
    Score: 0.075
  2. Chen X, Yang Q, Zhang M, Graner M, Zhu X, Larmonier N, Liao M, Yu W, Deng Q, Zhou B. Diagnosis of active tuberculosis in China using an in-house gamma interferon enzyme-linked immunospot assay. Clin Vaccine Immunol. 2009 Jun; 16(6):879-84.
    View in: PubMed
    Score: 0.066
  3. Graner MW, Zeng Y, Feng H, Katsanis E. Tumor-derived chaperone-rich cell lysates are effective therapeutic vaccines against a variety of cancers. Cancer Immunol Immunother. 2003 Apr; 52(4):226-34.
    View in: PubMed
    Score: 0.044
  4. Yu Y, Jin D, Hu S, Zhang Y, Zheng X, Zheng J, Liao M, Chen X, Graner M, Liu H, Jin Q. A novel tuberculosis antigen identified from human tuberculosis granulomas. Mol Cell Proteomics. 2015 Apr; 14(4):1093-103.
    View in: PubMed
    Score: 0.025
  5. Qiu Z, Zhang M, Zhu Y, Zheng F, Lu P, Liu H, Graner MW, Zhou B, Chen X. Multifunctional CD4 T cell responses in patients with active tuberculosis. Sci Rep. 2012; 2:216.
    View in: PubMed
    Score: 0.020
  6. Li G, Zeng Y, Chen X, Larmonier N, Sepassi M, Graner MW, Andreansky S, Brewer MA, Katsanis E. Human ovarian tumour-derived chaperone-rich cell lysate (CRCL) elicits T cell responses in vitro. Clin Exp Immunol. 2007 Apr; 148(1):136-45.
    View in: PubMed
    Score: 0.014
  7. Zeng Y, Graner MW, Thompson S, Marron M, Katsanis E. Induction of BCR-ABL-specific immunity following vaccination with chaperone-rich cell lysates derived from BCR-ABL+ tumor cells. Blood. 2005 Mar 01; 105(5):2016-22.
    View in: PubMed
    Score: 0.012
  8. Zeng Y, Graner MW, Feng H, Li G, Katsanis E. Imatinib mesylate effectively combines with chaperone-rich cell lysate-loaded dendritic cells to treat bcr-abl+ murine leukemia. Int J Cancer. 2004 Jun 10; 110(2):251-9.
    View in: PubMed
    Score: 0.012
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.

Copyright © 2024 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)